WebApr 5, 2024 · Therefore, DKK1 may be a potential target for anti-AFPGC therapy. Clinical trials have been conducted combining DKN-01, an antibody to DKK1, with tislelizumab and chemotherapy as first-line treatments for patients with GC and gastroesophageal junction cancer, with a preliminary objective response rate (ORR) of 68% and disease control … WebA Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. ... Arm: Experimental Drug DKN-01 150 mg Cohort 1A Dose Level 1: DKN-01 300 mg intravenously (IV) on Days 1 and 15, docetaxel 75 mg/m2 on Day 1 every 3 weeks (21- day cycles).

Combination of DKN-01 and Nivolumab in Previously Treated …

WebDKN-01 combined with pembrolizumab was well tolerated with no new safety signals. Antitumor activity was enriched in anti-PD-1/PD-L1-naïve GEJ/GC patients whose tumors expressed high DKK1. WebJun 21, 2024 · DKN-01 is in clinical trials in patients with gastroesophageal cancer, alone and in combination with paclitaxel, ... develop, and commercialize our drug product candidates; ... colonial center box office

FDA Grants DKN-01 Orphan Drug Status for Gastric/GEJ Cancer

WebApr 1, 2024 · Expertise in the clinical drug development life cycle, multiple therapeutic areas, including rare disease, anti-infectives, ... DKK1 is a predictive biomarker for response to DKN-01: ... WebArm: Experimental Drug Atezolizumab DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d). During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA … WebSep 4, 2024 · and filtration techniques, followed by aseptic fill-finish to produce DKN-01 drug product. DKN -01 was administered as a 30-minute IV infusion on days 1 and 15 of a 21-day cycle. colonial ceiling fans with lights